ProfileGDS5678 / 1439476_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 30% 30% 35% 30% 29% 30% 62% 78% 32% 30% 31% 30% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7337631
GSM967853U87-EV human glioblastoma xenograft - Control 22.6815430
GSM967854U87-EV human glioblastoma xenograft - Control 32.6927830
GSM967855U87-EV human glioblastoma xenograft - Control 42.7497735
GSM967856U87-EV human glioblastoma xenograft - Control 52.6288330
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7437929
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7198730
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7300162
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3800478
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7080532
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6696330
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6714731
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6797330
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6758130